InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.00%
)
US TECH 100
19,220.00
(
-0.30%
)
Dow Jones
42,196.52
(
0.00%
)
Brent Oil
75.27
(
0.87%
)
Bitcoin
60,306.05
(
-0.52%
)
Post# of 253269
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: dewophile post# 211341

Tuesday, 05/16/2017 10:03:10 AM

Tuesday, May 16, 2017 10:03:10 AM

Post# of 253269
>>I think it's fair to say that efficacy data are going to be on par between the 2 drugs, but we don't know about safety yet

We don't really know this yet - AKBA drug is much less potent and (at least for daily dosing) may be near the top of their dose response curve.

Note that Vifor can terminate this agreement completely within 12 months after the topline vada data is disclosed.

Note also that this is not a deal with Fresenius US - it is a deal with an associated distributor.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up